a16z Says AI Could Reshape Pharmaceutical R&D Economics
Andreessen Horowitz argues that AI could improve drug-development success rates while reducing development time and cost, potentially making pharmaceutical R&D platforms more valuable. A separate report says Geodesic Intelligence’s NovaAtom-Lite outperformed AlphaFold 3 and IsoDDE on benchmark tests. MIT Technology Review China notes that the proposed benefits still require validation through laboratory experiments and clinical results.
The reports present AI as a potential foundation for faster and more repeatable drug discovery, while emphasizing that benchmark performance and computer simulations do not establish safer, more effective or commercially successful medicines.
This source provides an excerpt. Continue reading on the original site.
#Andreessen Horowitz#NovaAtom-Lite#Geodesic Intelligence#Isomorphic Labs#AlphaFold 3#IsoDDE#Eli Lilly